Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage I Bladder Cancer AJCC v8: early-phase trial registry
7 of 8 indexed Stage I Bladder Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 7 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Stage I Bladder Cancer AJCC v8: 8 US clinical trials tracked, 7 recruiting.
Stage I Bladder Cancer AJCC v8 is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, Davis, running 2 of these trials.
Enrollment posture brief
Registry condition stage-i-bladder-cancer-ajcc-v8
OPEN 7 | RECR 88% | LATE 1 | EARLY 5 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Diseases (88% recruiting · 8 trials)
Stage I Bladder Cancer AJCC v8 lists 7 open slots (88% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage I Bladder Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage I Bladder Cancer AJCC v8 is recruiting above its size-band peers.
7 of 8 indexed trials (87.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage I Bladder Cancer AJCC v8 research.
University of California, Davis accounts for 2 of 8 trials (25%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Stage I Bladder Cancer AJCC v8 enrolment sits around 160 participants.
Median target enrolment is 160 among the 8 trials that report a genuine target (sentinel values excluded). 3 of those (37.5%) plan for fewer than 100 participants.
-
Stage I Bladder Cancer AJCC v8 research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Mayo Clinic
NCT06350734
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Alliance for Clinical Trials in Oncology
NCT07000084
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
NCT06770582
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
University of Washington
NCT07302230
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
NCT06704191
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
University of California, Davis
NCT05843448
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
NCT06173349
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
NCT04164082
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage I Bladder Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage I Bladder Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage I Bladder Cancer AJCC v8 page
8 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Stage I Bladder Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of California, Davis sponsors the most Stage I Bladder Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See University of California, Davis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage I Bladder Cancer AJCC v8 condition card totals 8 registered trials; most-linked intervention Cystoscopy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.